Abbvie Inc ABBV

$274.36 -6.76 (-2.40%)

Valuation

Market cap
488,465,248,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
25.06
Forward PE
19.50
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
6,408,788
Avg volume
4,599,934
Day's range
$273.70 – $283.43
Shares out
1,766,793,000
Stochastic %K
99%
Beta
0.24
Analysts
Strong Sell
Price target
$281.70

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 13, 7:32 PM
$SLS $2.5B $MRNA The Share Price will continue climbing until we get the Registrational Phase 3 Results and then the share Price Launches. - the Positive P3 Result is worth Close to $50B to Big Pharma - Don't be Surprised when this rigged $2.5B Mcap is $25B / $125 per share and Climbing, for the same reason $MRNA ran from $20 to $225 and added $50B in market value in the days after its Phase 3 Cancer vaccine results were announced. $ABBV • Imminent 80th Event PR and GPS P3 Results • Gps Immunotherapy is getting Fda GREENLIGHT to Treat 50,000 Patients Each year + 100,000 AML patients CURRENTLY in Remission - 100,000 right out of the GATE. • The Co Estimated a Minimum of $300K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev for 5+ Years. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $125 Per Share.
0 replies
Rayvio_News_Filter Oct 13, 7:16 PM
$ABBV 🏥 AbbVie Inc. presented new Phase 3 AFFIRM data showing subcutaneous SKYRIZI (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates versus placebo in moderately to severely active Crohn's disease, supporting an FDA application for subcutaneous induction dosing. More market highlights: https://rayvio.app/?utm_source=lifatpt
0 replies
55X_ROI_Q1_2026 Oct 13, 7:00 PM
$SLS for Years when Doctors like Dr. Yair Levy, the Dir. of Hematological Research at BAYLOR MED, Dr. Jamy from UAB, and Dr. Tsirigotis, Dr's treating actual SLS REGAL Phase 3 Patients, were saying Aza+VEN/BAT was effective in Obtaining Remission, but did NOT lead to Durable Survival due to its toxicty - and Stating on the RECORD - MOS w BAT was only 6-8 months ... We Still had the VIALE-M / Aza +VEN PH 3 Trial Out There -- in First Remission CR1 --- Now WE ALL KNOW BAT / FAILED - VIALE-M FAILED to Increase Survival for AML First Remission CR1 Patients. ITS FAILED THE SLS Second Remission CR2 Patients AS WELL... $MRNA $ABBV
0 replies
SniperPro Oct 13, 6:37 PM
$ABBV The biotechs really took the train downtown! 🚆😂 This too shall pass. 🙏✨
0 replies
V9RDPUMA Oct 13, 5:59 PM
$ABBV WTF happened?
0 replies
55X_ROI_Q1_2026 Oct 13, 5:00 PM
$SLS $MRNA Someone Knows Something: Dr. Tsirigotis - the clinician who treats More Actual Phase 3 REGAL patients than any other doctor "I strongly believe Gps will reach the study primary endpoint". "BAT is toxic, .. extremely poor .. median overall survival 5-7 months". Since then, we know BAT - has FAILED to increase survival in 5 TRIALS - including 3 large Phase 3 Trials $ABBV for AML Remission maintenance. • BAT has Failed the SLS CONTROL ARM Patients as well. The miraculous survival we are seeing, is solely due to GPS - Gps is doing what its done in all Prior Trials, Prevent Relapse and Extend Survival 2x 4x OS advantages, including in 2 Phase 2 Trials for AML Remission Maintenance. OCCAM'S RAZOR
0 replies
MQuick Oct 13, 4:52 PM
$GANX its time $MRK $RHHBY $ABBV $SNY
0 replies
55X_ROI_Q1_2026 Oct 13, 4:08 PM
$SLS $MRNA This $2.4B / $12 rigged Mcap/ share price will be $25B / $120 per share for the same reason $MRNA ran from $20 to $225 and added $50B in market value in the days after its Phase 3 Cancer vaccine results were announced. $ABBV Expect the SLS Share Price to Climb from here on out to the Imminent 80th Event PR and the GPS Phase 3 Results - a FDA Green Light to treat 50,000 AML Remission Patients Each Year. • Gps Immunotherapy is getting Fda GREENLIGHT to Treat 100,000 AML patients CURRENTLY in Remission - right out of the GATE. • The Co Estimated a Minimum of $300K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev for 5+ Years. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $125 Per Share. //
0 replies